A Phase I/III Randomized, Double-blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156/AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants with Conditions Causing Immune Impairment (NCT05648110)
SUPERNOVA [Phase 3]
This trial is Currently recruiting
Registration number NCT05648110
Program & service
This trial is being run with the Infectious Diseases service, and as part of the Infectious Diseases program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Dr Catherine Morrissey
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTRIf you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.